Literature DB >> 8951954

Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear.

T Inoue1, K Tsuchiya, T Koyama.   

Abstract

A typical antipsychotic drugs (atypical APDs), such as clozapine, ORG5222, and olanzapine, have been suggested to possess anxiolytic activity in the conflict test and elevated plus-maze test, while several studies have suggested that typical APDs are not anxiolytic in several models of anxiety. We investigated the effects of typical and atypical APDs on the acquisition and expression of conditioned fear-induced freezing. Drugs were administered subcutaneously to male Sprague-Dawley rats 30 min before foot shock stress (the VI60s schedule, 2.5 mA for 30 min). Twenty-four hours after foot shock, freezing behavior of rats was observed in the shock chamber without shocks. The atypical APD clozapine (0.3-10 mg/kg) dose-dependently inhibited the acquisition of conditioned freezing. Candidates for atypical APDs, ORG5222 (0.1-1 mg/kg), olanzapine (1-10 mg/kg), and raclopride (3-30 mg/kg), also reduced the acquisition of conditioned freezing in a dose-dependent manner. Typical APDs, haloperidol (3 mg/kg), spiperone (0.1-1 mg/kg) and nemonapride (1 mg/kg) had significant inhibitory effects on the acquisition of conditioned freezing, but their effects were reduced at higher doses. Chlorpromazine, a typical APD, showed about 50% inhibition of the acquisition of conditioned freezing at the dose of 10 mg/kg, but did not reveal significant inhibition at any of the doses (3-30 mg/kg). The ED50S (mg/kg) for inhibiting the acquisition of conditioned freezing significantly correlated with the Ki values for D4 dopaminergic receptors, but not with the Ki values for other monoamine and acetylcholine receptors. On the other hand, clozapine or haloperidol did not change the expression of conditioned freezing. These results suggest that protective effects of clozapine and other antipsychotic drugs on the acquisition of conditioned freezing may be mediated by blockade of D4 receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951954     DOI: 10.1016/s0091-3057(96)00064-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  Higher striatal dopamine transporter density in PTSD: an in vivo SPECT study with [(99m)Tc]TRODAT-1.

Authors:  Marcelo Q Hoexter; Gustavo Fadel; André C Felício; Mariana B Calzavara; Ilza R Batista; Marilia A Reis; Ming C Shih; Roger K Pitman; Sérgio B Andreoli; Marcelo F Mello; Jair J Mari; Rodrigo A Bressan
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

Review 2.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Effects of olanzapine infusions to the ventral tegmental area on lordosis and midbrain 3alpha,5alpha-THP concentrations in rats.

Authors:  Cheryl Frye; Angela Seliga
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

4.  Extinction memory is impaired in schizophrenia.

Authors:  Daphne J Holt; Kelimer Lebron-Milad; Mohammed R Milad; Scott L Rauch; Roger K Pitman; Scott P Orr; Brittany S Cassidy; Jared P Walsh; Donald C Goff
Journal:  Biol Psychiatry       Date:  2008-11-04       Impact factor: 13.382

5.  Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?

Authors:  Mariana Bendlin Calzavara; Wladimir Agostini Medrano; Raquel Levin; Sonia Regina Kameda; Monica Levy Andersen; Sergio Tufik; Regina Helena Silva; Roberto Frussa-Filho; Vanessa Costhek Abílio
Journal:  Schizophr Bull       Date:  2008-02-16       Impact factor: 9.306

6.  Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide.

Authors:  Alexa Mead; Ming Li; Shitij Kapur
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

Review 7.  Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines.

Authors:  Giampaolo Perna; Alciati Alessandra; Balletta Raffaele; Mingotto Elisa; Diaferia Giuseppina; Cavedini Paolo; Nobile Maria; Caldirola Daniela
Journal:  Int J Mol Sci       Date:  2016-04-13       Impact factor: 5.923

8.  Behavioral Effects of Systemic, Infralimbic and Prelimbic Injections of a Serotonin 5-HT2A Antagonist in Carioca High- and Low-Conditioned Freezing Rats.

Authors:  Laura A León; Vitor Castro-Gomes; Santiago Zárate-Guerrero; Karen Corredor; Antonio P Mello Cruz; Marcus L Brandão; Fernando P Cardenas; J Landeira-Fernandez
Journal:  Front Behav Neurosci       Date:  2017-07-07       Impact factor: 3.558

9.  GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.

Authors:  Elena Filatova; Anastasiya Kasian; Timur Kolomin; Ekaterina Rybalkina; Anelya Alieva; Lyudmila Andreeva; Svetlana Limborska; Nikolay Myasoedov; Galina Pavlova; Petr Slominsky; Maria Shadrina
Journal:  Front Pharmacol       Date:  2017-02-28       Impact factor: 5.810

10.  A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.

Authors:  James M Prosser; Samantha Yard; Annie Steele; Lisa J Cohen; Igor I Galynker
Journal:  BMC Psychiatry       Date:  2009-05-26       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.